# Immunovant Sciences GmbH: Phase 3 study terminated, 233 enrolled (Generalized Myasthenia Gravis)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Immunovant Sciences GmbH |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis |
| NCT ID | NCT05403541 |
| Phase | Phase 3 |
| Status | terminated |
| Conditions | Generalized Myasthenia Gravis |
| Intervention types | drug |
| Target enrollment | 233 |
| Site countries | United States, Argentina, Brazil, Canada, Georgia, Germany, Hungary, Italy, Japan, Mexico, Poland, Romania |
| Posted | 2022-06-03 |
| Planned start | 2022-06-27 |
| Event | Terminated |
| Event date | 2026-08-07 |
| Last update posted | 2026-09-14 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- Phase 3: multi-site, larger budget.
- 233 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05403541). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.